Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

doi:10.1200/JCO.2014.58.3302

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Mar 2015

Mazières Julien, Zalcman Gérard, Crinò Lucio, Biondani Pamela, Barlesi Fabrice, Filleron Thomas, Dingemans Anne-Marie C, Léna Hervé, Monnet Isabelle, Rothschild Sacha I, Cappuzzo Federico, Besse Benjamin, Thiberville Luc, Rouvière Damien, Dziadziuszko Rafal, Smit Egbert F, Wolf Jurgen, Spirig Christian, Pecuchet Nicolas, Leenders Frauke, Heuckmann Johannes M, Diebold Joachim, Milia Julie D, Thomas Roman K, Gautschi Oliver

Abstract excerpt

PURPOSE: Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains. PATIENTS AND METHODS: In the absence of a prospective clinical trial in Europe, we conducted a retrospective study in centers that tested for ROS1 rearrangement. Eligible patients had stage IV lung adenocarcinoma, had ROS1 rearrangement according to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Gene Rearrangement

Share to In Situ Hybridization, Fluorescence

Share to Protein-Tyrosine Kinases

Share to Pyrazoles

Share to Pyridines

Share to Translocation, Genetic

Source

Open in PubMed

Identifiers

PMID: 25667280
DOI: 10.1200/JCO.2014.58.3302

Genes

ROS1
ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.PMID 25667280Read ↗

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung CancerSemantic proximity Read ↗

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.Semantic proximity Read ↗

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to DateSemantic proximity Read ↗

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant AlterationsSemantic proximity Read ↗

ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersSemantic proximity Read ↗

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted TherapiesSemantic proximity Read ↗

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to CrizotinibSemantic proximity Read ↗

[ROS1-Translocations in Non-Small Cell Lung Cancer].Semantic proximity Read ↗

Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas.Semantic proximity Read ↗

<scp>ROS</scp>1 expression and translocations in non‐small‐cell lung cancer: clinicopathological analysis of 1478 casesSemantic proximity Read ↗

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.Semantic proximity Read ↗

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.